

# Clinical and molecular response of acute myeloid leukemia harboring non-canonical *FLT3* N676K driver mutations to contemporary *FLT3* inhibitors

Gregory W. Roloff,<sup>1</sup> Frank Wen,<sup>1</sup> Aubrianna Ramsland,<sup>1</sup> Andrew S. Artz,<sup>2</sup> Satyajit Kosuri,<sup>1</sup> Wendy Stock,<sup>1</sup> Olatoyosi Odenike,<sup>1</sup> Richard A. Larson,<sup>1</sup> Hongtao Liu,<sup>1</sup> Lucy A. Godley,<sup>1</sup> Michael J. Thirman,<sup>1</sup> Anand A. Patel,<sup>1</sup> Christopher K. Daugherty,<sup>1</sup> Adam S. DuVall,<sup>1</sup> Mariam T. Nawas,<sup>1</sup> Emily Dworkin,<sup>1</sup> Geoffrey D. Wool,<sup>3</sup> Sandeep Gurbuxani,<sup>3</sup> Carrie Fitzpatrick,<sup>3</sup> Jeremy P. Segal,<sup>3</sup> Peng Wang<sup>3</sup> and Michael W. Drazer<sup>1</sup>

<sup>1</sup>Section of Hematology/Oncology, The University of Chicago, Chicago, IL; <sup>2</sup>Division of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA and <sup>3</sup>Department of Pathology, The University of Chicago, Chicago, IL, USA

Correspondence:  
M.W. Drazer - mdrazer@medicinebsd.uchicago.edu

<https://doi.org/10.3324/haematol.2022.282148>

Supplementary Materials for:

**Clinical and molecular response of AML harboring non-canonical *FLT3* N676K driver mutations to *FLT3* inhibitors**

Gregory W. Roloff<sup>1</sup>, Frank Wen<sup>1</sup>, Aubrianna Ramsland<sup>1</sup>, Andrew S. Artz<sup>2</sup>, Satyajit Kosuri<sup>1</sup>, Wendy Stock<sup>1</sup>, Olatoyosi Odenike<sup>1</sup>, Richard A. Larson<sup>1</sup>, Hongtao Liu<sup>1</sup>, Emily Dworkin<sup>1</sup>, Geoffrey D. Wool<sup>3</sup>, Carrie Fitzpatrick<sup>3</sup>, Megan E. McNerney<sup>3</sup>, Jeremy P. Segal<sup>3</sup>, Peng Wang<sup>3</sup> and Michael W. Drazer<sup>1\*</sup>

<sup>1</sup> Section of Hematology/Oncology, The University of Chicago, Chicago, IL

<sup>2</sup> Division of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte CA


<sup>3</sup> Department of Pathology, The University of Chicago, Chicago IL

Table of Contents:


**Figure S1.** Network of comutations associated with *FLT3* variants in the cohort.

**Figure S2.** Comutational correlation analysis of longitudinal NGS data

**Figure S3.** Intra-patient mutation profiles detected on longitudinal NGS.




**Figure S1. Network of mutations associated with *FLT3* variants in the cohort.**  
 Circos plot of mutational networks of *FLT3* N676K-mutated AML patients in the analysis. Chord thickness reflects the number of co-occurrences between two genes.



**Figure S2. Computational correlation analysis of longitudinal NGS data.**

Pearson's correlation coefficient was across variant allele frequencies (VAFs) for all observed instances of mutations that co-occur at least twice in the dataset. Values approaching 1.0 on the heatmap indicate a strong propensity for mutational co-occurrence while more negative values denote mutual exclusivity between two mutational events. White asterisks indicate  $p < 0.05$ .



**Figure S3. Intra-patient mutation profiles detected on longitudinal NGS.**

Longitudinal NGS demonstrates VAF kinetics over time. Each cycle indicated on the x-axis represents a repeat NGS assessment over the clinical course.